Advertising Console

    Allergan Readies Defense As It Fights Valeant For Votes

    Wochit Headline News

    by Wochit Headline News

    Allergan may take on debt to buy back its own shares as part of a multi-faceted plan to thwart a $53 billion takeover bid by Valeant Pharmaceuticals and activist investor William Ackman. The company is also considering making acquisitions of its own and more spending cuts to increase shareholder value, Chief Executive David Pyott said in an interview, outlining steps to build support for Allergan, best known for its Botox anti-wrinkle injections, to remain a standalone company.